Details
Category: Volume 06 Issue 07 July 2018
Hits: 1268

Title: Role of Lipid Panel in Patients of Chronic Renal Disease: Hospital Based Study

Authors: Kavita Arya, Dr Pankaj Kumar Meena, Dr Kush Manna

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i7.14

Abstract

Chronic renal failure (CRF) is a state which results from a permanent and usually progressive reduction in renal function. Chronic renal failure (CRF) is also known as chronic kidney disease (CKD). Chronic kidney disease (CKD) is a long term condition caused by damage to both kidneys. Patients with chronic kidney disease (CKD) are at an increased risk for cardiovascular disease and have a higher prevalence of hyperlipidaemia. Most characteristic lipid abnormality are increased level of serum triglycerides, very low density lipoprotein (VLDL), and low levels of high density lipoprotein. A total of 50 patients having CKD was compared by the same no. Of control group individuals. Manual methods were used to detected the abnormalities in Lipid Panel. All the Parameter of Lipid Panel were significantly raised such as TG, Cholesterol, LDL-Cholesterol, etc. As comparied with that of control group. Conclusion of the study that there is significant dyslipidemia, raised in chronic renal failure patients as compared to healthy controls. Higher urea, creatinine, uric acid correlates well with development of chronic renal failure. So, It gives us a clue regarding possible metabolic relation in chronic renal failure patient. Hence, this study has been a step forward to find relation of multiple metabolic factors with chronic renal failure and raises a fundamental issue of need of further research in this direction which can help in better understanding of this disease and in developing new therapeutic strategies in treatment of chronic renal failure patients.

Keywords: CKD, Cholesterol, TG, HDL, LDL.

References

  1. Winearls CG. Chronic Renal failure In: Warrell DA, Cox TM, Firth JD, Benz EJ, Eds. Oxford text book of Medicine 4th edn, Vol 3. New York, Oxford University press 2003;263-278.
  2. Draibe SA. Chronic Renal Failure. In: Schor N, organizer. Guide to Sao Paulo (SP): 2002; Manole.
  3. Rutkowski B, Chmielewski M. Lipid disturbances in chronic renal failure-pathomechanisms and treatment. Rocz Akad Med Bialymst. 2004; 49: 139-144.
  4. Rutkowski B, Lososowska R, Krol E, et al. [Patho mechanism of hyperlipoproteinemia in chronic renal failure]. Pol Merkur Lekarski. 2003; 15:322-323; discussion 323-325. Polish.
  5. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort withmild renal insufficiency. Kidney Int 1999;56:2214-9.
  6. Oda H, Keane WF. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 1998;13(1):45-49.
  7. Ul Amin N, Raja T. M, Javaid A, Mudassar Z. and Asad, M.R.A prospective study evaluating urea and creatinine levels in chronic renal failure pre and post dialysis: Journal of cardiovascular disease,Vol.2 No.2,2014;2330-4596.
  8. Dipika B, Varsha J, Tejas S, Kapil G and Nikunj M. Impactof Hemodialysis on Lipid Profile Among Chronic Renal Failure Patients. India2013; 3(7):1-3.
  9. Fuh, MM, Lee CM, Jen CY and Shen DC. The effect of chronic renal failure on HDL kinetics. Kidney International.
  10. Bowers, L.D.Clin Chem.1980;26:551.
  11. Bartel, H.Clin.Chem.Acta1972;37:193.
  12. Slot,C.Scand.J.Clin Lab.Invest1965; 17:381.
  13. Young D.S.Clin.Chem.1975;21:266D
  14. Jacobs N.J, Van Denmark, P.J, Arch. Biochem Biophys.1960; 88: 250-255.
  15. Koditscheck L. Umbriet, W. W,J. Bacteriol 1969; 1063-1068.
  16. Richmond W, Clin. Chem.1973; 19:1350.
  17. Tarbutton P. N. Gunter C.R. Clin.Chem.1974;20:724.
  18. Allain C.C et al, Clin Chem.1974 ;20:470.
  19. Richmond W. Scan. J. Clin, Lab. Invest. 29, Suppl. 26, Abst. 3. 25 (1972).
  20. Young D. S. et al, 21, D (1975).

Corresponding Author

Dr Pankaj Kumar Meena

Biochemist, Department of Biochemistry

NIMS Medical College, Jaipur